Kezar Life Sciences (NASDAQ:KZR – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday, Marketbeat.com reports.
Kezar Life Sciences Price Performance
NASDAQ:KZR opened at $0.83 on Wednesday. The firm has a market cap of $60.10 million, a PE ratio of -0.59 and a beta of 0.20. The company’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.70. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. Kezar Life Sciences has a 12 month low of $0.52 and a 12 month high of $1.14.
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, equities analysts anticipate that Kezar Life Sciences will post -1.2 EPS for the current fiscal year.
Institutional Trading of Kezar Life Sciences
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Featured Stories
- Five stocks we like better than Kezar Life Sciences
- Trading Halts Explained
- When Is the Best Time to Invest in Mutual Funds?
- How to Invest in Blue Chip Stocks
- Is NVIDIA Stock in a Correction or Consolidation?
- How to Use the MarketBeat Stock Screener
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.